134 related articles for article (PubMed ID: 37354152)
1. A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas.
Blakeley JO; Le LQ; Lee SY; Ly I; Rhodes SD; Romo CG; Sarin KY; Staedtke V; Steensma MR; Wolkenstein P;
J Invest Dermatol; 2023 Aug; 143(8):1351-1357. PubMed ID: 37354152
[No Abstract] [Full Text] [Related]
2. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel.
Wataya-Kaneda M; Watanabe Y; Nakamura A; Yamamoto K; Okada K; Maeda S; Nimura K; Saga K; Katayama I
J Am Acad Dermatol; 2023 Apr; 88(4):877-880. PubMed ID: 36334988
[No Abstract] [Full Text] [Related]
3. Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
Br J Dermatol; 2024 Jan; 190(2):e20. PubMed ID: 38262593
[No Abstract] [Full Text] [Related]
4. How to score the impact of treatment on cutaneous neurofibromas in clinical trials.
Ortonne N
Br J Dermatol; 2024 Jan; 190(2):147-148. PubMed ID: 38084905
[No Abstract] [Full Text] [Related]
5. Neurofibromatosis type 1: Factors associated with flare-ups of cutaneous neurofibromas at puberty.
Skayem C; Fertitta L; Diaz E; Jannic A; Ferkal S; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e158-e159. PubMed ID: 36226401
[No Abstract] [Full Text] [Related]
6. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
[TBL] [Abstract][Full Text] [Related]
7. Eruptive neurofibromas in pregnancy.
Yahya H; Sani H
Ann Afr Med; 2020; 19(2):150-152. PubMed ID: 32499474
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis.
Pasmant E; Ortonne N; Rittié L; Laurendeau I; Lévy P; Lazar V; Parfait B; Leroy K; Dessen P; Valeyrie-Allanore L; Perbal B; Wolkenstein P; Vidaud M; Vidaud D; Bièche I
J Neuropathol Exp Neurol; 2010 Jan; 69(1):60-9. PubMed ID: 20010302
[TBL] [Abstract][Full Text] [Related]
9. High-resolution 400K oligonucleotide array comparative genomic hybridization analysis of neurofibromatosis type 1-associated cutaneous neurofibromas.
Asai A; Karnan S; Ota A; Takahashi M; Damdindorj L; Konishi Y; Hossain E; Konishi H; Nagata A; Yokoo K; Hosokawa Y
Gene; 2015 Mar; 558(2):220-6. PubMed ID: 25562418
[TBL] [Abstract][Full Text] [Related]
10. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I.
Malhotra N; Levy JMS; Fiorillo L
Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862
[TBL] [Abstract][Full Text] [Related]
11. Single-cell PCR performed with neurofibroma Schwann cells reveals the presence of both alleles of the neurofibromatosis type 1 (NF1) gene.
Stark M; Assum G; Krone W
Hum Genet; 1995 Nov; 96(5):619-23. PubMed ID: 8530015
[TBL] [Abstract][Full Text] [Related]
12. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1.
Ehara Y; Yamamoto O; Kosaki K; Yoshida Y
J Dermatol; 2018 Jan; 45(1):53-57. PubMed ID: 28891076
[TBL] [Abstract][Full Text] [Related]
13. Multiple nodular plexiform neurofibromas in a neurofibromatosis 1 family: a familial tendency? A case report and review of the literature.
Tamer E; Yalçin B; Alli N
Int J Dermatol; 2003 May; 42(5):357-8. PubMed ID: 12755971
[No Abstract] [Full Text] [Related]
14. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
15. Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1.
Romo CG; Sarin KY; Blakeley JO
Br J Dermatol; 2024 Jan; 190(2):145-146. PubMed ID: 38123358
[No Abstract] [Full Text] [Related]
16. [Cutaneous neurofibromas in neurofibromatosis-1].
Ortonne N
Ann Dermatol Venereol; 2008; 135(6-7):525-8. PubMed ID: 18598811
[No Abstract] [Full Text] [Related]
17. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
[TBL] [Abstract][Full Text] [Related]
18. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
[TBL] [Abstract][Full Text] [Related]
19. Segmental neurofibromatosis.
Schultz ES; Kaufmann D; Tinschert S; Schell H; von den Driesch P; Schuler G
Dermatology; 2002; 204(4):296-7. PubMed ID: 12077526
[TBL] [Abstract][Full Text] [Related]
20. Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region.
Kehrer-Sawatzki H; Schmid E; Fünsterer C; Kluwe L; Mautner VF
Am J Med Genet A; 2008 Mar; 146A(6):691-9. PubMed ID: 18265407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
